• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Neman-Ebrahim Yousha

    6/9/25 7:35:23 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NTHI alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Neman-Ebrahim Yousha

    (Last) (First) (Middle)
    23975 PARK SORRENTO
    SUITE 205

    (Street)
    CALABASAS CA 91302

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    06/05/2025
    3. Issuer Name and Ticker or Trading Symbol
    NEONC TECHNOLOGIES HOLDINGS, INC. [ NTHI ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Clinical Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    No securities are beneficially owned.
    /s/ Yousha Neman-Ebrahim 06/09/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NTHI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NTHI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NTHI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President Heshmatpour Amir F bought $14,785 worth of CommonStock (2,000 units at $7.39), increasing direct ownership by 0.11% to 1,762,000 units (SEC Form 4)

      4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

      5/23/25 9:31:11 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Chen Thomas C bought $40,002 worth of shares (5,468 units at $7.32), increasing direct ownership by 1% to 551,668 units (SEC Form 4)

      4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

      5/23/25 9:30:24 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO Garnett Keithly bought $4,921 worth of shares (675 units at $7.29), increasing direct ownership by 0.28% to 240,900 units (SEC Form 4)

      4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

      5/23/25 9:28:12 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NTHI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NeOnc Technologies Secures Board Approval for $50 Million Strategic Partnership with Quazar Investment

      CALABASAS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced it has achieved a key milestone toward closing its previously announced strategic transaction with Quazar Investment: formal approval from NeOnc's Board of Directors. On June 30, 2025, NeOnc's Board unanimously approved the company's participation in the contemplated $50 million equity investment and MENA region expansion under a non-binding term sheet with Quazar. This Board approval marks the first of five required milestones in the transaction c

      7/10/25 9:00:00 AM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NeOnc Technologies Holdings, Inc. Joins Russell Microcap® Index

      CALABASSAS, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, has joined the Russell Microcap® Index following the conclusion of the 2025 Russell indexes annual reconstitution. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks ranking them by total market capitalization. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes pr

      7/9/25 9:00:00 AM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform

      CALABASAS, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced it has signed a non-binding term sheet with Quazar Investment to form a new UAE-based investment and clinical platform focused on the Middle East and North Africa (MENA) region. The non-binding term sheet outlines the formation of NuroMENA Holdings Ltd, a wholly owned holding company of NeOnc, which will oversee the incorporation of NuroCure, an Abu Dhabi onshore operating subsidiary. NuroCure will be responsible for initiating and managing clinical tria

      7/8/25 9:00:00 AM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NTHI
    SEC Filings

    See more
    • NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

      7/10/25 5:00:32 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by NeOnc Technologies Holdings Inc.

      EFFECT - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

      6/17/25 12:15:11 AM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by NeOnc Technologies Holdings Inc.

      424B5 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

      6/16/25 4:46:53 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NTHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Clinical Officer Neman-Ebrahim Yousha was granted 133,000 shares (SEC Form 4)

      4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

      6/9/25 7:40:19 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Neman-Ebrahim Yousha

      3 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

      6/9/25 7:35:23 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Chiang Ming-Fu (Alan) was granted 50,000 shares, disposed of 5,994 shares, exercised 117,188 in-the-money shares at a strike of $12.00 and sold $1,433,912 worth of shares (57,696 units at $24.85), increasing direct ownership by 15% to 390,216 units (SEC Form 4)

      4/A - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

      6/5/25 7:25:44 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NTHI
    Leadership Updates

    Live Leadership Updates

    See more
    • NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

      USC brain tumor authority to accelerate four clinical trials including lead asset NEO100 nearing Phase 2a completion ahead of schedule Appointment bolsters FDA approval path while company explores AI and quantum computing to enhance drug delivery platform CALABASAS, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced the appointment of Josh Neman, PhD as its new Chief Clinical Officer (CCO). Dr. Neman brings with him a distinguished career at the intersection of cancer neuroscience, translational

      6/6/25 9:00:00 AM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care